RNS Number : 6528D
BlackRock Group
29 October 2020
Ap19
FORM
8.3
IRISH TAKEOVER PANEL
DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013
DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE
1.
KEY
INFORMATION
|
Nameofpersondealing
(Note
1)
|
BlackRock, Inc.
|
|
Companydealtin
|
Willis Towers Watson plc
|
|
Classofrelevantsecuritytowhichthe dealingsbeingdisclosedrelate
(Note
2)
|
US$0.000304635 ordinary shares
|
|
Date
of
dealing
|
28 October 2020
|
2.
INTERESTS AND SHORT POSITIONS
(a)
Interests
and
short
positions
(following
dealing)
in
the
class
of
relevant
security
dealt
in
(Note
3)
|
|
Long
|
Short
|
|
|
Number
|
|
(%)
|
Number
|
|
(%)
|
|
(1)Relevantsecurities
|
9,484,984 (7.36%)
|
469 (0.00%)
|
|
(2)
Derivatives
(other
than
options)
|
1,973,914 (1.53%)
|
2,922 (0.00%)
|
|
(3)Optionsandagreementstopurchase/sell
|
0 (0.00%)
|
0 (0.00%)
|
|
Total
|
11,458,898 (8.89%)
|
3,391 (0.00%)
|
| |
|
|
|
|
|
|
(b)
Interests and short positions in relevant securities of the company, other than the class dealt in
(Note
3)
|
Classofrelevantsecurity:
|
Long
|
Short
|
|
|
Number
|
|
(%)
|
Number
|
|
(%)
|
|
(1)Relevantsecurities
|
|
|
|
(2)
Derivatives
(other
than
options)
|
|
|
|
(3)Optionsandagreementstopurchase/sell
|
|
|
|
Total
|
|
|
| |
|
|
|
|
|
|
Ap20
1.
DEALINGS
(Note
4)
(a) Purchases and sales
|
Purchase/sale
|
Numberofrelevantsecurities
|
Priceperunit
(Note
5)
|
|
Purchase
|
2,134
|
USD 193.5129
|
|
Purchase
|
1,024
|
USD 193.9100
|
|
Purchase
|
10
|
USD 195.9000
|
|
Sale
|
5,065
|
USD 193.9100
|
|
Sale
|
61,289
|
USD 194.5712
|
|
Sale
|
31
|
USD 195.4750
|
Please note: there was also a Transfer Out of 1,150 Shares
(b) Derivatives transactions (other than options transactions)
|
Productname,
e.g.
CFD
|
Natureoftransaction
(Note
6)
|
Numberofrelevantsecurities
(Note
7)
|
Priceperunit
(Note
5)
|
|
|
|
|
|
(c) Options transactions in respect of existing relevant securities
(i) Writing, selling, purchasing or varying
|
Productname,
e.g.
call
option
|
Writing,
selling,purchasing,varyingetc.
|
Numberofsecurities towhichtheoptionrelates
(Note
7)
|
Exercise price
|
Type,
e.g.American,Europeanetc.
|
Expiry date
|
Optionmoney paid/receivedperunit
(Note
5)
|
|
|
|
|
|
|
|
|
(ii) Exercising
|
Productname,
e.g.
call
option
|
Numberofsecurities
|
Exercisepriceper unit
(Note
5)
|
|
|
|
|
(d) Other dealings (including transactions in respect of new securities) (Note 4)
|
Nature
of
transaction
(Note
8)
|
Details
|
Price
per
unit
(if applicable)
(Note 5)
|
|
Return of Stock on Loan
|
33,200
|
N/A
|
Ap21
2. OTHER INFORMATION
Agreements, arrangements or understandings relating to options or derivatives
Full details of any agreement, arrangement or understanding between the person disclosing and
any other person relating to the voting rights of any relevant securities under any option referred to
on
this
form
or
relating
to
the
voting
rights
or
future
acquisition
or
disposal
of
any
relevant securities to
which any derivative referred to on this form is referenced. If none, this should be stated.
None
Is a Supplemental Form 8 attached?
(Note
9)
NO
|
Dateofdisclosure
|
29 October 2020
|
|
Contact
name
|
Jana Blumenstein
|
|
Telephone
number
|
+44 20 7743 3650
|
|
If
aconnectedEFM,nameofofferee/offerorwithwhichconnected
|
|
|
If
aconnectedEFM,statenatureofconnection
(Note
10)
|
|
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com. RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy. END
ISEMLBTTMTJTBJM
|
